Skip to main content
. Author manuscript; available in PMC: 2022 Feb 28.
Published in final edited form as: Eur J Pharm Biopharm. 2018 May 29;129:162–174. doi: 10.1016/j.ejpb.2018.05.033

Fig. 9.

Fig. 9.

(A) Experimental and adjusted concentration-time profiles of paromomycin after oral administration of an immediate-release tablet of 250 mg of paromomycin during a phase I contractile activity. (B) Experimental and simulated concentration-time profiles of paromomycin after oral administration of an immediate-release tablet of 250 mg of paromomycin during a phase II contractile activity. All observed data were obtained from literature [11].